Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
This dose is the highest dose meeting tolerability and safety criteria in the phase I study of (in)GSH in PD
Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively
It is not FDA-approved for any medical condition
Precipitation after refrigeration: Some peptides precipitate at cold temperatures even when they dissolve at room temperature
AOD-9604 is unlikely to interact with most medications because its mechanism is confined to adipocyte lipolysis and it does not bind plasma proteins at significant levels
